What is the long-term trend for Neuropace, Inc.'s cash cash equivalents and short term investments?

Over 4 years (2021 to 2025), Neuropace, Inc.'s cash cash equivalents and short term investments has grown at a -14.7% compound annual growth rate (CAGR), from $115.6M to $61.1M.

Neuropace, Inc. NPCE Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

AmphenolAPH

$4.58B+174%

Travel + LeisureTNL

$456M+24.3%

Warrior Met CoalHCC

$210.55M-54.5%

Main Street CapitalMAIN

$20.79M-81.0%

Cabot CorporationCBT

$252M+18.3%

UnifirstUNF

$151.79M-21.0%

Other financials

Income statement

See full

Revenue$22.1M-2.0%

Gross profit$18.0M+4.1%

Operating income-$5.6M-8.2%

Net income-$6.7M-1.5%

EPS (diluted)-$0.20+4.8%

Balance sheet

See full

Cash & equivalents$15.6M-42.4%

Total debt$70.5M-3.7%

Total equity$14.5M-40.4%

Total assets$98.9M-10.3%

Cash flow

See full

Operating cash flow-$5.9M+21.1%

CapEx$117.0K+216%

Free cash flow-$6.0M+20.0%

Valuation

See full

Market cap$557.77M+63.4%

Enterprise value$612.6M+58.1%

P/S5.6×+1.6×

Profitability

See full

Gross margin78.3%+3.5pp

Operating margin-16.8%-3.5pp

Net margin-21.7%-4.5pp

FCF margin-10.3%-3.5pp

Returns & leverage

See full

Return on equity-111.4%-13.1pp

Debt / equity4.9×+1.9×

Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neuropace, Inc.'s cash cash equivalents and short term investments?: Neuropace, Inc. (NPCE) reported cash cash equivalents and short term investments of $54M in Q1 2026.
How has Neuropace, Inc.'s cash cash equivalents and short term investments changed year-over-year?: Neuropace, Inc.'s cash cash equivalents and short term investments decreased by 18.6% year-over-year, from $66.3M to $54M.
What is the long-term trend for Neuropace, Inc.'s cash cash equivalents and short term investments?: Over 4 years (2021 to 2025), Neuropace, Inc.'s cash cash equivalents and short term investments has grown at a -14.7% compound annual growth rate (CAGR), from $115.6M to $61.1M.